Patient-Derived Xenografts to Reduce Cancer Health Disparities

Launched by UNIVERSITY OF CALIFORNIA, DAVIS · May 27, 2020

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how different types of cancer, specifically bladder, lung, stomach, and liver cancers, affect patients from various racial and ethnic backgrounds. The researchers are using a method called patient-derived xenografts, which involves taking cancer cells from patients and growing them in lab animals. This helps scientists learn more about how these cancers behave and respond to treatments. By studying these differences, the goal is to improve cancer treatments and reduce health disparities that certain groups face.

To participate in the trial, you must be an adult currently receiving treatment for one of the cancers mentioned. You'll need to provide your consent, which means you agree to participate and understand what the study involves. Unfortunately, children, pregnant women, and individuals who cannot give consent themselves are not eligible. If you decide to join, you can expect to provide some samples for research, and your contributions could help advance cancer care for everyone, especially those facing greater challenges in treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer)
• • Signed informed consent that will be put on file
• Exclusion Criteria:
• • No informed consent obtained
• • Specimen unacceptable/degraded/etc.
• • Individuals who are not yet adults (infants, children, teenagers)
• • Pregnant women
• • Prisoners
• • Adults unable to consent